Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System

NCT07870265 is registered in ClinicalTrials.gov with Masaryk Memorial Cancer Institute as lead sponsor.

NCT NCT07870265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
Lead sponsor
Masaryk Memorial Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
October 20, 2026
Completion date
December 20, 2027
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e mutation, unresectable metastatic melanoma